Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Grazoprevir - Merck and Co

Drug Profile

Grazoprevir - Merck and Co

Alternative Names: MK-5172

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Class Antivirals; Carbamates; Carboxylic acids; Cyclopropanes; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 08 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy) in Puerto Rico (PO)
  • 08 Sep 2021 Discontinued - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in France, Germany, Israel, Australia, Canada, Austria, Puerto Rico, United Kingdom, Sweden, Poland, New Zealand, Lithuania (PO)
  • 21 Apr 2021 Merck & Co completes a phase II extension trial for Hepatitis C in Germany, Italy, Sweden, Hungary, France, Denmark, Spain, Finland, Estonia, the Netherlands, Lithuania, Czech Republic, Austria, Poland, Greece, and United Kingdom and USA (PO) (NCT01667081) (EudraCT2012-002232-85)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top